Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease

Blood

Volumn 118, Issue 12, 2011, Pages 3376-3383

  Hillery, Cheryl A ^a,b   Kerstein, Patrick C ^a   Vilceanu, Daniel ^a   Barabas, Marie E ^a   Retherford, Dawn ^a,b   Brandow, Amanda M ^a   Wandersee, Nancy J ^a,b   Stucky, Cheryl L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINYL) 3 [4 (TRIFLUOROMETHYL)BENZYL]UREA; HC 030031; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLD; DISEASE SEVERITY; ERYTHROCYTE; HEAT; HYPERSENSITIVITY; HYPOXIA; MALE; MECHANICAL STIMULATION; MOUSE; NOCICEPTION; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; SICKLE CELL ANEMIA; STIMULUS RESPONSE; TEMPERATURE SENSITIVITY; THERMOREGULATION;

EID: 80053217106     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-327429     Document Type: Article

References (50)

1. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101. (Pubitemid 351651552)
2. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am. 2005;19(5):785-802. (Pubitemid 41427110)
3. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11-16.
4. Jacob E, Miaskowski C, Savedra M, et al. Changes in intensity, location, and quality of vaso-occlusive pain in children with sickle cell disease. Pain. 2003;102(1-2):187-193. (Pubitemid 36298875)
5. Nolan VG, Zhang Y, Lash T, Sebastiani P, Steinberg MH. Association between wind speed and the occurrence of sickle cell acute painful episodes: results of a case-crossover study. Br J Haematol. 2008;143(3):433-438.
6. Jones S, Duncan ER, Thomas N, et al. Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. Br J Haematol. 2005;131(4):530-533. (Pubitemid 43899652)
7. Pászty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997; 278(5339):876-878. (Pubitemid 27467927)
8. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994; 53(1):55-63. (Pubitemid 24238751)
9. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32(1):77-88.
10. El Kouhen R, Surowy CS, Bianchi BR, et al. A-425619 [1-isoquinolin-5-yl- 3-(4-trifluoromethylbenzyl)- urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Ther. 2005;314(1):400-409. (Pubitemid 41058278)
11. Honore P, Wismer CT, Mikusa J, et al. A-425619 [1-isoquinolin-5-yl-3-(4- trifluoromethyl-benzyl)- urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther. 2005;314(1): 410-421. (Pubitemid 41058279)
12. Mills C, McMackin M, Jaffe R, et al. Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat. Neuroscience. 2008;156(1):165-174.
13. Garami A, Shimansky YP, Pakai E, et al. Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. J Neurosci. 2010;30(4):1435-1440.
14. Kwan KY, Glazer JM, Corey DP, Rice FL, Stucky CL. TRPA1 modulates mechanotransduction in cutaneous sensory neurons. J Neurosci. 2009;29(15):4808-4819.
15. Kerstein PC, Del Camino D, Moran MM, Stucky CL. Pharmacological blockade of TRPA1 inhibits mechanical firing in nociceptors. Mol Pain. 2009;5:19.
16. Vilceanu D, Honore P, Hogan QH, Stucky CL. Spinal nerve ligation in mouse upregulates TRPV1 heat function in injured IB4-positive nociceptors. J Pain. 2010;11(6):588-599.
17. Vilceanu D, Stucky CL. TRPA1 mediates mechanical currents in the plasma membrane of mouse sensory neurons. PloS One. 2010;5(8): e12177.
18. Eid SR, Crown ED, Moore EL, et al. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol Pain. 2008;4:48.
19. Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science. 2000; 288(5464):306-313. (Pubitemid 30226186)
20. Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997; 389(6653):816-824. (Pubitemid 27462969)
21. Kanai Y, Nakazato E, Fujiuchi A, Hara T, Imai A. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology. 2005; 49(7):977-984. (Pubitemid 41503297)
22. McGaraughty S, Chu KL, Brown BS, et al. Contributions of central and peripheral TRPV1 receptors to mechanically evoked and spontaneous firing of spinal neurons in inflamed rats. J Neurophysiol. 2008;100(6):3158-3166.
23. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11(2):129-151. (Pubitemid 39619075)
24. Braz JM, Nassar MA, Wood JN, Basbaum AI. Parallel "pain" pathways arise from subpopulations of primary afferent nociceptor. Neuron. 2005;47(6):787-793. (Pubitemid 41266946)
25. Scherrer G, Imamachi N, Cao YQ, et al. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell. 2009;137(6): 1148-1159.
26. Kohli DR, Li Y, Khasabov SG, et al. Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood. 2010;116(3):456-465.
27. Dampier CD, Setty BN, Logan J, Ioli JG, Dean R. Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. J Pediatr. 1995;126(3):461-467.
28. Jordt SE, Tominaga M, Julius D. Acid potentiation of the capsaicin receptor determined by a key extracellular site. Proc Natl Acad Sci U S A. 2000; 97(14):8134-8139. (Pubitemid 30460785)
29. Ryu S, Liu B, Qin F. Low pH potentiates both capsaicin binding and channel gating of VR1 receptors. J Gen Physiol. 2003;122(1):45-61. (Pubitemid 36859131)
30. Henrich M, Buckler KJ. Acid-evoked Ca2+ signalling in rat sensory neurones: effects of anoxia and aglycaemia. Pflugers Arch. 2009;459(1):159-181.
31. Graido-Gonzalez E, Doherty JC, Bergreen EW, et al. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998;92(7): 2551-2555. (Pubitemid 28453000)
32. Russell FA, Fernandes ES, Courade JP, Keeble JE, Brain SD. Tumour necrosis factor alpha mediates transient receptor potential vanilloid 1-dependent bilateral thermal hyperalgesia with distinct peripheral roles of interleukin-1beta, protein kinase C and cyclooxygenase-2 signalling. Pain. 2009;142(3):264-274.
33. Hwang SW, Cho H, Kwak J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000;97(11):6155-6160. (Pubitemid 30367539)
34. Plant TD, Zollner C, Mousa SA, Oksche A. Endothelin- 1 potentiates capsaicin-induced TRPV1 currents via the endothelin A receptor. Exp Biol Med (Maywood). 2006;231(6):1161-1164. (Pubitemid 43845597)
35. Patwardhan AM, Scotland PE, Akopian AN, Hargreaves KM. Activation of TRPV1 in the spinal cord by oxidized linoleic acid metabolites contributes to inflammatory hyperalgesia. Proc Natl Acad Sci U S A. 2009;106(44):18820-18824.
36. Nath KA, Katusic ZS, Gladwin MT. The perfusion paradox and vascular instability in sickle cell disease. Microcirculation. 2004;11(2):179-193. (Pubitemid 39619078)
37. Bank N, Aynedjian HS, Qiu JH, et al. Renal nitric oxide synthases in transgenic sickle cell mice. Kidney Int. 1996;50(1):184-189. (Pubitemid 26323712)
38. Pritchard KA, Jr., Ou J, Ou Z, et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2004;286(4):L705-L714. (Pubitemid 38365054)
39. Conran N, Oresco-Santos C, Acosta HC, et al. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Br J Haematol. 2004;124(4):547-554. (Pubitemid 38230601)
40. Yoshida T, Inoue R, Morii T, et al. Nitric oxide activates TRP channels by cysteine S-nitrosylation. Nat Chem Biol. 2006;2(11):596-607. (Pubitemid 44610344)
41. Miyamoto T, Dubin AE, Petrus MJ, Patapoutian A. TRPV1 and TRPA1 mediate peripheral nitric oxide- induced nociception in mice. PLoS One. 2009;4(10):e7596.
42. Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci. 2009;32(12):611-618.
43. Aley KO, Messing RO, Mochly-Rosen D, Levine JD. Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C. J Neurosci. 2000;20(12):4680-4685. (Pubitemid 30396633)
44. Joseph EK, Levine JD. Hyperalgesic priming is restricted to isolectin B4-positive nociceptors. Neuroscience. 2010;169(1):431-435.
45. Szallasi A, Cortright DN, Blum CA, Eid SR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov. 2007;6(5):357-372. (Pubitemid 46705200)
46. Lambert DG. Capsaicin receptor antagonists: a promising new addition to the pain clinic. Br J Anaesth. 2009;102(2):153-155.
47. Gavva NR. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol Sci. 2008;29(11):550-557.
48. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Res Rev. 2009;60(1):267-277.
49. Lehto SG, Tamir R, Deng H, et al. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1Hinden- 4-yl)-3-(2-(piperidin-1-yl)-4- (trifluorom ethyl) phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther. 2008;326(1):218-229. (Pubitemid 351872146)
50. Yang D, Luo Z, Ma S, et al. Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension. Cell Metab. 2010;12(2):130-141.